Navigation Links
Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
Date:6/27/2008

editable by GSK against outstanding amounts under the loan facility. Exelixis expects to submit the XL184 proof-of-concept package to GSK for its development election in the third quarter of 2008.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's website at http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation: statements related to the timing of a phase 3 clinical trial for XL184; the future development and potential efficacy of Exelixis' compounds; the timing of a potential compound selection and milestone payment by GSK; and the timing for submission of the XL184 proof-of-concept package to GSK. Words such as "expect," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current plans, assumptions, beliefs and expectations. Forward- looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the potential failure of Exelixi
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 The largest international professional organization ... and therapeutic derivatives thereof has endorsed an educational ... about the challenges of adulterated herb and botanical ... The Society for Medicinal Plant and ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... In this time period, doctors did not know that they ... the death of vulnerable patients. In the same way, medical ... be unwittingly transmitting herpes viruses to their patients. The CBCD ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... May 19 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... Quill(TM) SRS wound closure product line is now available ... at https://ecommerce.angiotech.com/Main/Home.aspx . The Quill SRS products are ... Polydioxanone (PDO), MONODERM(TM), Nylon and Polypropylene product lines. , ...
... with Novel Mode of ActionMOUNTAIN VIEW, Calif., May ... that data from the company,s PROTECT-1 (the Prospective ... Phase II/III clinical trial of Traficet-EN(TM) (CCX282-B) in ... in an oral session at the upcoming 2009 ...
... -- Leading pharmaceutical and biotech,companies are drawing on ... enhance their R&D productivity, leverage academic,insights and diversify ... a population,base that is representative of key Asian ... companies to test and develop new solutions for,Asia ...
Cached Biology Technology:Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line 2Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line 3Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 3ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 5Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 2Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 3Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 4Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 5
(Date:4/24/2014)... Allan, PhD, a scientist at Western University and the ... spreads or metastasizes to the lung. , Breast cancer ... two cause of cancer-related deaths among women in North ... have a high success rate, but once the disease ... particular, the lung is one of the most common ...
(Date:4/24/2014)... at Ludwig-Maximilians-Universitaet (LMU) in Munich have identified the ... to discriminate between viral and endogenous RNAs in ... take control of cellular metabolism and hijack cellular ... process is dependent on viral RNA molecules that ... RNA viruses) and/or newly synthesized in the host ...
(Date:4/24/2014)... be improved with new insights into the make-up of ... the Amazon Basin have revealed unprecedented detail of the ... by comparing satellite maps with hundreds of field plots. ... more accurately the amount of carbon each tree can ... schemes, in which trees are given a cash value ...
Breaking Biology News(10 mins):New study helps to explain why breast cancer often spreads to the lung 2Viral infections: Identifying the tell-tale patterns 2Viral infections: Identifying the tell-tale patterns 3Amazon rainforest survey could improve carbon offset schemes 2
... states are invited to attend the annual meeting of ... Oct. 28 and 29 in Spokane, Wash. The ... policy and technology of carbon capture and storage (CCS). ... carbon sequestration technologies, the economics of CCS, regulatory and ...
... Zeitlinger, Ph.D., Stowers Institute Assistant Investigator, has been ... National Institutes of Health (NIH). Dr. Zeitlinger was ... million over five years. The awards enable recipients ... biomedical and behavioral science. "Nothing is ...
... assistant bioengineering professor at the UC San Diego Jacobs School ... tissue engineering. With a new $1.5 million New Innovator Award ... be able to do just that. , The awards, ... small number of new investigators who have exceptional creativity and ...
Cached Biology News:Julia Zeitlinger selected for NIH Director's New Innovator Award 2Generation innovation: Young UC San Diego bioengineer to use NIH grant to fuel tissue engineering 2Generation innovation: Young UC San Diego bioengineer to use NIH grant to fuel tissue engineering 3
... Immunogen KLH-conjugated, synthetic ... 54-75 (RRGPHRNPG-PGDDDGQRSRSSS) of mouse p19ARF. ... to amino acids 62-75. Clone ... Routinely evaluated by immunoblot. ...
Request Info...
Hybridization cassette for one slide...
Request Info...
Biology Products: